Annexin Pharmaceuticals

Focus: Annexin Pharmaceuticals is a Swedish biopharmaceutical company focused on biologic therapies for cardiovascular indications. Founded in 2014 and publicly listed, the company operates at a pre-commercial stage with early-stage pipeline programs.

Cardiovascular Neurology Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Annexin Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Annexin Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Annexin A5

Retinal Vein Occlusion

Phase 2

Clinical Trials (3)

NCT07259928Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

Phase 2

Help build intelligence for Annexin Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to biologic drug development in high-value cardiovascular and neurology markets with meaningful unmet clinical needs
Public company status provides equity upside potential and organizational stability versus private biotech
Opportunity to contribute to Phase 2 advancement of lead program (Annexin A5) toward potential Phase 3 readiness

Watch Out For

Currently zero open job postings signals minimal active hiring and limited near-term career mobility within the organization
Early-stage pipeline (only 1 Phase 2 program, no Phase 3 catalysts) carries high clinical and commercial execution risk
Missing financial data on cash position, R&D spend, and revenue limits visibility into company stability and runway

Generated by Claude from Annexin Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT05532735Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

Phase 2

NCT04850339First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2014

Portfolio: 3 clinical trials

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

2 pipeline

Marketed

Pipeline